Aptinyx Inc. Common Stock
APTX
APTX was delisted on the 18th of May, 2023.
3 hedge funds and large institutions have $24K invested in Aptinyx Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 29 closing their positions.
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
91% less funds holding
Funds holding: 32 → 3 (-29)
99% less capital invested
Capital invested by funds: $2.44M → $24K (-$2.42M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 29
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.11M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$649K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$232K |
| 4 |
BlackRock
New York
|
-$86.1K |
| 5 |
Renaissance Technologies
New York
|
-$56K |
APTX Hedge Fund Activity: Q2 2023 in Review
3 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aptinyx Inc. Common Stock (APTX) for Q2 2023, worth a combined $24K — down 99% from $2.44M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of APTX and 0 opened new positions — a net loss of 29 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $1.11M sold.
- 3 institutional investors held Aptinyx Inc. Common Stock (APTX) as of Q2 2023, down from 32 in Q1 2023.
- Funds reported $24K of Aptinyx Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
- 0 funds opened new Aptinyx Inc. Common Stock positions in Q2 2023 and 29 closed out, a net change of -29 holders.
- The largest Aptinyx Inc. Common Stock seller in Q2 2023 was Bain Capital Life Sciences Investors, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2023.